News/ News/ R&D AZ drug for hard-to-treat heart failure has mixed results in trial Phil Taylor AstraZeneca, cardiovascular disease, heart failure, MPO inhibitor 0 Comment AstraZeneca has reported the first phase 2 results with a drug for heart failure with preserved ejection fraction Share X AZ drug for hard-to-treat heart failure has mixed results in trial https://pharmaphorum.com/news/az-drug-for-hard-to-treat-heart-failure-has-mixed-results-in-trial/